EP0592488A1 - Dimethylamino-hydroxy-alkandiphosphonsäure und sie enthaltenden pharmazeutische präparate - Google Patents

Dimethylamino-hydroxy-alkandiphosphonsäure und sie enthaltenden pharmazeutische präparate

Info

Publication number
EP0592488A1
EP0592488A1 EP92913148A EP92913148A EP0592488A1 EP 0592488 A1 EP0592488 A1 EP 0592488A1 EP 92913148 A EP92913148 A EP 92913148A EP 92913148 A EP92913148 A EP 92913148A EP 0592488 A1 EP0592488 A1 EP 0592488A1
Authority
EP
European Patent Office
Prior art keywords
dimethylamino
acid
hydroxy
diphosphonic
alkan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92913148A
Other languages
English (en)
French (fr)
Inventor
Giuseppe Guainai-Ricci
Sergio Rosini
Murizio Mian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Gentili SpA
Original Assignee
Istituto Gentili SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Gentili SpA filed Critical Istituto Gentili SpA
Publication of EP0592488A1 publication Critical patent/EP0592488A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to new dimethyl- amino-hydroxy-alkan diphosphonic acids and the salts 0 thereof.
  • the invention relates to a method for their production, as well as the pharmaceutical compositions containing these products.
  • the above group of compounds has been used with advantage, inter alia, in the pharmaceutical field for the treatment of diseases associated with disturbances of the bone metabolism, 0 such as osteoporosis, Paget's disease, osteolysys caused by tumourand hyperparathyrodism, osteoarthrosis, arthritis and the like.
  • diseases associated with disturbances of the bone metabolism 0 such as osteoporosis, Paget's disease, osteolysys caused by tumourand hyperparathyrodism, osteoarthrosis, arthritis and the like.
  • the 4-amino-l-hydroxy-butan-l,1-diphosphonic acid and its derivatives has proven particularly effective in this respect.
  • the above compound is active and effective at concentrations much lower than other similar diphosphonic compounds with correspondingly lower unwanted side effects.
  • Dimethylamino-hydroxy-alkan diphosphonic acids and their derivatives are also known which show similar properties and activity when alkyl group is propyl or butyl.
  • US patent No.4054598 discloses, inter alia, the 3-dimethylamino-hydroxy-propan-l,l- diphosphonic acid, its preparation and uses
  • US patent No.4624947 discloses the 4-dimethylamino- hydroxy-butan-1,1-diphosphonic acid, its preparation and uses, under the form both of the acid and of its water soluble salts.
  • the latter compounds are also described as possbile radionuclide carriers to particular biological tissues, such as for example the bone tissue, for the execution of scintigraphic analyses (see for instance Europeant patents No.96932 and 96933) .
  • the known processes for the preparation of phosphonic acids and in particular of amino-hydroxy- alkan-diphosphonic acids comprise reacting the corresponding amino-carboxylic acid with a mixture of phosphorous acid and phosphorus halide, such as phosphorus trichloride, and hydrolyzing the polyemeric products thus obtained in order to give the wanted diphosphonic acid to be recovered under purified form, for example, by crystallization.
  • a mixture of phosphorous acid and phosphorus halide such as phosphorus trichloride
  • the reaction is conducted in the presence of an organic inert substance, for example a chlorinated hydrocarbon such as chlorobenzene, while the hydrolysis is conducted with a not oxidizing strong acid.
  • an organic inert substance for example a chlorinated hydrocarbon such as chlorobenzene
  • the same reaction is conducted without either solvents or inert substances and with different reactants molar ratios, using water as hydrol zing agent and recovering the wanted amino diphosphonic acid by precipitation with an alcohol which is added to the hydrolized solution.
  • the dimethylamino-l-hydroxy-alkan-1,1-diphosphonic acids can be prepared from the corresponding dimethylamino-l-amino-alkan-l-hydroxy-1,1-diphosphonic acids by reaction with nitrous acid, salts thereof and compounds forming nitrous acid under the reaction conditions,while the reactant acid can be obtained from the corresponding nitrile by reaction with phosphorous halide under anhydrous conditions in the presence of a solvent or an inert inorganic diluent followed by hydrolysis in water.
  • the reactant acid can be obtained by phosphonylation of the corresponding dimethylated aminoacid with phosphorous acid in the presence of PCI3 or by other phosphonylation reactions well known to the person skilled in the art.
  • Another object of the invention is to provide pharmaceutical compositions comprising the dimethylamino-l-hydroxy-alkan-1,1-diphosphonic acids, their derivatives and water soluble salts according to the present invention for the administration to patients suffering from diseases associated with disturbances of bone metabolism.
  • the compounds according to the present invention are the 5-dimethylamino-l-hydroxy- pentan-1,1-diphosphonic acid (DAPeDP) and the 6- dimethyla_ ⁇ ino-l-hydroxy-hexan-l,1-diphosphonic acid (DAEDP) , as well as their non-toxic, pharmaceutically acceptable, water-soluble salts.
  • DAPeDP 5-dimethylamino-l-hydroxy- pentan-1,1-diphosphonic acid
  • DEDP 6- dimethyla_ ⁇ ino-l-hydroxy-hexan-l,1-diphosphonic acid
  • both DAPeDP and DABDP can be obtained respectively from the 5-dimethylamino-l-amino-pentan-l,1-diphosphonic acid and from the 6-dimethyl-l-amino-esan-l,l-diphosphonic acid by reaction with nitrous acid or with reactants capable of forming nitrous acid under the reaction conditions.
  • the dimethylated amino-alkyl diphosphonic acids used as reactants can be obtained by reaction of 5-dimethylamino-valeronitrile and, respectively, of 6- dimethylamino-capronitrile with an amount of PBr3 slightly higher than the stoichiometric under anhydrous conditions and in the presence of an inert solvent or diluent.
  • the product obtained in this way is then treated with hot water to hydrolize the polymers thus formed.
  • the molar ratios among the reactants are quite variable, generally comprised between 1:1:1 and 1:20:5 according to whether a solvent is used or not. Preferred molar ratio of 1:5:2 in the absence of a solvent is used.
  • the product obtained in this way is subjected to hydrolysis which can be performed both with a non- oxidizing strong acid in aqueous solution and for a longer time with water only.
  • the 5-dimethylamino valeric acid and the 6-dimethylamino caproic acid can be obtained by dialkylation according to methods known in the art.
  • n is equal to 4 or 5.
  • the method consists in reacting the 5-amino valeric acid, or respectively- the 6-amino caproic acid with formic acid and formaldehyde 40% solution with molar ratios generally comprised between 1:2:2 and 1:10:4 under reflux for a time variable from 0.5 and 3 hours.
  • the mixture of reaction is then concentrated under vacuum and at a temperature of 100-120°C until distillation has gone to end and the residual product thus obtained is directly passed to the reaction with H3PO3 and PX3 in the previously indicated, known molar ratio without the need of isolating any intermediate product.
  • the product resulting from the reaction can be easily recrystallized from water if necessary.
  • Example 1 131,2 g (1 mole) of 6-amino-caproic acid are dissolved in 190 ml (5 moles) of 99% formic acid and 170 ml (2,2 moles) of a 40% solution formic aldehyde; the solution is kept under reflux for 3 hours and then concentrated under vacuum up to about 110°C until the end of distillation.
  • the reaction apparatus is placed under nitrogen and 246 g (3 moles) of H3PO3 are added; the temperature is raised to 90°C and 363 ml (4,14 moles) of PCI3 are gradually added. The mixture is kept under low reflux for 3 hours and then cooled.
  • Example 2 164.8 g (0,54 moles) of 6-dimethylamino-hydroxy- hexan-l,l-diphosphonic acid are obtained whose identity and high purity are confirmed with the analyses.
  • Example 2 206 g (1,5 moles) of PCI3 are dissolved in a mixture of 5-dimethylamino-valerianic acid (145,2 g, 1 mole) and H3PO3 (246 g, 3 moles) by a dropwise addition under anhydrous conditions, under vacuum and stirring; the solution is kept under slow PCI3 reflux for 3 hours and then caused to cool.
  • PCI3 206 g (1,5 moles) of PCI3 are slowly added under stirring to a suspension obtained by mixing 159.2 g (1 mole) of 6-dimethylamino caproic acid with 164 g (2 moles) of H3PO3 in 500 ml of chlorobenzene brought to 90°C under a nitrogen stream; the mixture is moderately refluxed for 3 hours and then is caused to cool. 500 ml of distilled water are then added slowly and under stirring, once any solid matter possibly present is separated and the acqueous phase is refluxed for 6 hours. After cooling and filtering with decolorizing charcoal an equal volume of methanol is added and the mixture is left under stirring for 24 hours.
  • the yield is equal to 63%.
  • the water-soluble salts of the acids according to the present invention can be obtained by complete or partial neutralization with inorganic, organic bases or quaternary ammonium, such as NaOH, KOH, NH OH, alkaline carbonates, alkanolamines, and the like, and isolating the salt by a following concentration up to crystallization or, alternately and more simply, by precipitation with a C1-C3 alcohol or acetone.
  • the diphosphonic acids according to the present invention and their saline derivatives are suitable for the preparation of pharmaceutical compositions useful in the therapeutic or preventive treatment of diseases associated with disturbances of bone metabolism, such as osteoporosis, Paget's disease, osteolysis caused by tumours and hyperparathyroidsm, osteoarthrosis, arthrytis and the like.
  • the toxicological studies which have been carried out have shown a toxicity of the compounds of the invention much lower than that of the corresponding non-methylated products. The results of these studies are summarized herebelow. a) 6-dimethylamino-l-hydroxy-hexan-l ,1- diphosphonic acid (DAEDP) .
  • compositions according to the present invention can be prepared in the form of: - tablets, capsules, granules, pills, for oral administration;
  • compositions are advantageously prepared in combination with inert excipients, such as sugars (saccharose, glucose, lactose) , starch and derivatives, cellulose and derivatives, fatty acids and salts thereof, polyalcohols, talc, aromatic esters.
  • inert excipients such as sugars (saccharose, glucose, lactose) , starch and derivatives, cellulose and derivatives, fatty acids and salts thereof, polyalcohols, talc, aromatic esters.
  • One capsule contains DAPeDP 25 mg lactose 84 mg hydrolyzed starch 5 mg talc 5 mg magnesium stearate 1 mg
  • One ampoule contains
  • DEDP 6- dimethylamino-hydroxyhexan-1,1-diphosphonic acid
  • the dosage range of the diphosphonic acids according to the present invention and of the relevant water-soluble saline derivative, according to the therapeutic use and referred to 1 Kg of body weight can be the following:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP92913148A 1991-06-26 1992-05-27 Dimethylamino-hydroxy-alkandiphosphonsäure und sie enthaltenden pharmazeutische präparate Withdrawn EP0592488A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITFI91160 1991-06-26
ITFI910160A IT1247034B (it) 1991-06-26 1991-06-26 Acidi dimetilamino-idrossi alchil difosfonici e loro sali, loro procedimento produttivo e composizioni farmaceutiche che li comprendono
PCT/IT1992/000058 WO1993000348A1 (en) 1991-06-26 1992-05-27 Dimethylamino-hydroxy-alkan diphosphonic acids and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
EP0592488A1 true EP0592488A1 (de) 1994-04-20

Family

ID=11349724

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92913148A Withdrawn EP0592488A1 (de) 1991-06-26 1992-05-27 Dimethylamino-hydroxy-alkandiphosphonsäure und sie enthaltenden pharmazeutische präparate

Country Status (8)

Country Link
EP (1) EP0592488A1 (de)
JP (1) JPH06508833A (de)
AU (1) AU2150792A (de)
CA (1) CA2112250A1 (de)
IT (1) IT1247034B (de)
MX (1) MX9203205A (de)
PT (1) PT100624B (de)
WO (1) WO1993000348A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303672B1 (it) 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
ES2336312T3 (es) * 2001-07-16 2010-04-12 Universite Paris 13 Procedimiento de preparacion de derivados de bisfosfonatos.
DE102014115154A1 (de) * 2014-10-17 2016-04-21 SCV-SpezialChemikalien-Vertrieb GmbH Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1194748B (it) * 1981-02-12 1988-09-28 Gentili Ist Spa Composizioni farmaceutiche per il trattamento di osteopatie
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9300348A1 *

Also Published As

Publication number Publication date
ITFI910160A1 (it) 1992-12-26
JPH06508833A (ja) 1994-10-06
IT1247034B (it) 1994-12-12
PT100624B (pt) 1999-07-30
WO1993000348A1 (en) 1993-01-07
AU2150792A (en) 1993-01-25
CA2112250A1 (en) 1993-01-07
MX9203205A (es) 1994-06-30
PT100624A (pt) 1993-10-29
ITFI910160A0 (it) 1991-06-26

Similar Documents

Publication Publication Date Title
US4621077A (en) Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom
US4304734A (en) 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
EP0252505B1 (de) 1-Hydroxy-3-(N-methyl-N-propylamino)propan-1,1-diphosphonsäure; Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel
US5661174A (en) Guanidinealkyl-1,1-bisphosphonic acid derivatives, process for their preparation and their use
JP4171702B2 (ja) 新規α−アミノ−Ｎ−（ジアミノホスフィニル）ラクタム誘導体
DE3540150A1 (de) Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP0243968B1 (de) Diacetylrheinsäure-Kaliumsalze und seine Verwendung zur Behandlung von Arthritis
JP2010502667A (ja) Ｓｎａｃ（サルカプロザートナトリウム）の製造法
US4608368A (en) 1-hydroxy-1,1-diphosphonic acids and cytostatic use thereof
DE69026964T2 (de) Gem-diphosphonsäuren, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
KR100269544B1 (ko) 구아니디노알킬-1,1-비스포스폰산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
Zygmunt Aziridine-2-phosphonic acid, the valuable synthon for synthesis of 1-amino-2-functionalized ethanephosphonic acids
WO1997002827A1 (en) Therapeutic use of 1-amino-3-(n,n-dimethylamino)-propyliden-1,1-bisphosphonic acid and its salts
DE69022593T2 (de) Neue methylenbisphosphonsäurederivate.
CN111233933A (zh) 一种米诺膦酸二聚体的合成方法
EP0592488A1 (de) Dimethylamino-hydroxy-alkandiphosphonsäure und sie enthaltenden pharmazeutische präparate
EP0166302A2 (de) 1-[Bis-(4-Fluorphenyl)methyl]-4-(3-phenyl-2-propenyl)-hexahydro-1H-1,4-diazepin und dieses enthaltende Mittel
KR900006133B1 (ko) 올-시스-1,3,5-트리아미노-2,4,6-시클로헥산트리올 유도체의 제조방법
CA1182128A (en) Phosphoramide derivatives, process for producing the same and medicines containing the same
EP0623623B1 (de) Komplex von 2-aminoäthansulfonsäure und zink
US5068228A (en) Use of a metal chelate of an alkylaminoester of phosphoric acid for prophytlaxis or therapy of a neuropathy
FI65261B (fi) Foerfarande foer framstaellning av farmakologiskt anvaendbart dinatriumsalt av n-(fosfonoacetyl)-l-asparaginsyra
WO1996033199A1 (en) Process for making 1-hydroxybisphosphonates
US20040138182A1 (en) Colchicine derivatives, process for preparing them, products obtained therefrom and use thereof
JPS59141544A (ja) ラクタムペプチド及びその製造方法、並びに該ペプチドを含有する医薬

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19951130